<DOC>
	<DOC>NCT01095991</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of AZD1656 on Sitagliptin pharmacokinetics and vice versa in patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients with confirmed type 2 diabetes mellitus for at least 2 months and treated with metformin. Body mass index between ≥19 and ≤42 kg/m2. Intake of another investigational drug within the last 30 days prior to enrolment. Clinically significant illness or clinically relevant trauma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus, Sitagliptin</keyword>
</DOC>